Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Azenta, Inc. (AZTA:NASDAQ), powered by AI.
Azenta, Inc. is currently trading at $22.59. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Azenta, Inc. on Alpha Lenz.
Azenta, Inc.'s P/E ratio is -18.5.
“Azenta, Inc. trades at a P/E of -18.5 (undervalued) with modest ROE of -3.2%.”
Ask for details →Azenta Inc. is a life sciences company that specializes in providing solutions for sample-based services and advanced automation systems. The company's primary function is to support pharmaceutical and biotech companies with their drug discovery, development, and production processes by offering comprehensive sample management and storage solutions. Azenta Inc. impacts several sectors within the life sciences industry, including biobanking, genomic and diagnostic testing, and cell therapy applications. By streamlining the management of biological samples, Azenta enhances the efficiency and accuracy of research and development activities. Azenta plays a significant role in the market by addressing the growing demand for efficient sample storage and data management solutions, helping companies to safeguard and optimize their valuable biological materials. With its innovative technology solutions, Azenta Inc. supports its clients in achieving critical breakthroughs in medical research, ultimately contributing to advancements in healthcare. The company’s services are crucial for ensuring sample integrity and compliance with regulatory standards, making it a trusted partner for organizations in need of reliable and scalable sample management capabilities.
“Azenta, Inc. trades at a P/E of -18.5 (undervalued) with modest ROE of -3.2%.”
Ask for details →Azenta, Inc. (ticker: AZTA) is a company listed on NASDAQ in the Healthcare sector (Medical Instruments & Supplies). It has approximately 3,000 employees. Market cap is $1.0B.
The current price is $22.59 with a P/E ratio of -18.53x and P/B of 0.6x.
ROE is -3.19% and operating margin is -3.65%. Annual revenue is $594M.